Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Acquired by Victory Capital Management Inc.

Victory Capital Management Inc. increased its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 36.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,403 shares of the biopharmaceutical company’s stock after purchasing an additional 4,695 shares during the period. Victory Capital Management Inc.’s holdings in Ocular Therapeutix were worth $119,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Great Point Partners LLC purchased a new position in Ocular Therapeutix during the fourth quarter worth $3,122,000. Artia Global Partners LP acquired a new stake in shares of Ocular Therapeutix during the fourth quarter valued at $1,962,000. Deltec Asset Management LLC increased its position in Ocular Therapeutix by 9.6% during the 2nd quarter. Deltec Asset Management LLC now owns 2,590,265 shares of the biopharmaceutical company’s stock worth $17,717,000 after purchasing an additional 226,181 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in Ocular Therapeutix by 1,142.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 662,672 shares of the biopharmaceutical company’s stock valued at $6,031,000 after purchasing an additional 609,328 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in Ocular Therapeutix by 41.4% in the 1st quarter. Vanguard Group Inc. now owns 7,235,131 shares of the biopharmaceutical company’s stock valued at $65,840,000 after purchasing an additional 2,117,029 shares in the last quarter. Hedge funds and other institutional investors own 59.21% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. Piper Sandler reiterated an “overweight” rating and set a $15.00 price target on shares of Ocular Therapeutix in a report on Friday, June 21st. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 target price on shares of Ocular Therapeutix in a research note on Thursday, August 1st. TD Cowen lowered Ocular Therapeutix from a “strong-buy” rating to a “hold” rating in a research note on Friday, June 21st. Finally, Robert W. Baird lowered their price objective on Ocular Therapeutix from $18.00 to $17.00 and set an “outperform” rating for the company in a research report on Thursday, August 8th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $15.67.

Ocular Therapeutix Stock Up 1.5 %

Shares of NASDAQ OCUL opened at $8.59 on Wednesday. The stock has a market capitalization of $1.33 billion, a PE ratio of -6.36 and a beta of 1.28. The company has a quick ratio of 16.55, a current ratio of 16.64 and a debt-to-equity ratio of 0.18. The firm has a fifty day moving average of $8.44 and a 200-day moving average of $7.40. Ocular Therapeutix, Inc. has a 52-week low of $2.00 and a 52-week high of $11.31.

Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.04). The firm had revenue of $16.40 million for the quarter, compared to analysts’ expectations of $15.85 million. Ocular Therapeutix had a negative net margin of 226.46% and a negative return on equity of 52.75%. Ocular Therapeutix’s revenue was up 7.9% on a year-over-year basis. During the same period last year, the firm posted ($0.27) EPS. On average, analysts anticipate that Ocular Therapeutix, Inc. will post -1.02 EPS for the current year.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.